Robust Amyloid Clearance in a Mouse Model of Alzheimer's Disease Provides Novel Insights Into the Mechanism of Amyloid-ßimmun
4124 • The Journal of Neuroscience, March 16, 2011 • 31(11):4124–4136 Neurobiology of Disease Robust Amyloid Clearance in a Mouse Model of Alzheimer’s Disease Provides Novel Insights into the Mechanism of Amyloid- Immunotherapy Allan Wang,1,2 Pritam Das,6 Robert C. Switzer III,7 Todd E. Golde,8 and Joanna L. Jankowsky2,3,4,5 1Department of Psychology, Rice University, Houston, Texas 77251, Departments of 2Neuroscience, 3Neurosurgery, and 4Neurology, and 5Huffington Center on Aging, Baylor College of Medicine, Houston, Texas 77030, 6Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida 32224, 7NeuroScience Associates, Knoxville, Tennessee 37934, and 8Department of Neuroscience, McKnight Brain Institute, Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, Florida 32610 Many new therapeutics for Alzheimer’s disease delay the accumulation of amyloid- (A) in transgenic mice, but evidence for clearance of preexisting plaques is often lacking. Here, we demonstrate that anti-A immunotherapy combined with suppression of A synthesis allows significant removal of antecedent deposits. We treated amyloid-bearing tet-off APP (amyloid precursor protein) mice with doxycycline to suppress transgenic A production before initiating a 12 week course of passive immunization. Animals remained on doxycycline for 3 months afterward to assess whether improvements attained during combined treatment could be maintained by monotherapy. This strategy reduced amyloid load by 52% and A42 content by 28% relative to pretreatment levels, with preferential clearance of small deposits and diffuse A surrounding fibrillar cores. We demonstrate that peripherally administered anti-A antibody crossed the blood–brain barrier, bound to plaques, and was still be found associated with a subset of amyloid deposits many months after the final injection.
[Show full text]